Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 597,300 shares, a growth of 30.7% from the December 31st total of 457,100 shares. Based on an average trading volume of 421,900 shares, the days-to-cover ratio is currently 1.4 days. Currently, 22.4% of the company's shares are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Hedge Funds Weigh In On Aligos Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALGS. AlphaMark Advisors LLC grew its position in shares of Aligos Therapeutics by 1,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company's stock worth $44,000 after buying an additional 1,000 shares during the period. Drive Wealth Management LLC purchased a new stake in Aligos Therapeutics in the fourth quarter worth about $916,000. Finally, Golden State Wealth Management LLC purchased a new stake in Aligos Therapeutics in the fourth quarter worth about $107,000. Hedge funds and other institutional investors own 60.43% of the company's stock.

Aligos Therapeutics Stock Performance

Shares of NASDAQ ALGS traded down $3.01 during midday trading on Monday, hitting $22.80. 168,057 shares of the company traded hands, compared to its average volume of 324,757. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $46.80. The stock has a 50-day moving average price of $32.79 and a 200 day moving average price of $19.28. The firm has a market cap of $81.83 million, a P/E ratio of -1.71 and a beta of 2.46.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The firm had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. During the same period in the prior year, the company posted ($10.25) EPS. As a group, equities analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).